TearScience recently introduced its new LipiFlow® Activator II treatment disposable, and announced results from a study that reportedly shows a single application of vectored thermal pulsation treatment for Meibomian Gland Dysfunction (MGD) added to existing therapy significantly improved signs and symptoms for individuals with positive biomarkers for Sjögren’s syndrome.
LipiFlow’s Activator reportedly consists of the scleral lens heating surface, the shield structure and the pulsation bladders, all of which directly interface with the patient oculus. The new LipiFlow Activator II treatment disposable reportedly meets the same standard for sterility as the original Activator, but uses a separate semi-permanent cable that remains connected to the LipiFlow Console. This allows the LipiFlow System to now include a reusable cable, helping to reduce waste.
Click here to read the full press release.
And TearScience recently reported the results of a physician-sponsored study that reviewed the medical records of 102 eyes of 59 patients who received a LipiFlow vectored thermal pulsation treatment for verified MGD, with 23 of these patients also testing positive for biomarkers associated with Sjögren’s syndrome.
Eight weeks after receiving the treatment, scores on the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire and measurements of tear breakup times (TBUT) reportedly improved in all patients, with no difference based on Sjögren’s syndrome status. Additionally, there were improvements from baseline to week eight in Meibomian Gland Score, although the results were slightly better for patients who did not test positive for Sjögren’s syndrome biomarkers.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.